Levothyroxine Sodium Tablet
NDC Package 67296-1908-3

11-digit billing NDC: 67296190803
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Levothyroxine Sodium tablets is hypothyroidismLevothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) SuppressionLevothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.Limitations of Use:Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium may induce hyperthyroidism [see Warnings and Precautions(5.1)]. This formulation utilizes a tablet delivery system. Marketed by Redpharm Drug, Inc, this product is identified by NDC 67296-1908 and is authorized under FDA application ANDA212399.

Identification & Billing

NDC Package Code
67296-1908-3
Package Description
30 TABLET in 1 BOTTLE
Product Code
67296-1908
11-Digit Billing Format
67296190803
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Levothyroxine Sodium
Non-Proprietary Name
Levothyroxine Sodium
Substance Name
Levothyroxine Sodium
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
LEVOTHYROXINE SODIUM 137 ug/1
Pharmacologic Class
Usage Information
HypothyroidismLevothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) SuppressionLevothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.Limitations of Use:Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium may induce hyperthyroidism [see Warnings and Precautions(5.1)]. Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

Regulatory & Marketing

Labeler Name
Redpharm Drug, Inc
Product Type
Human Prescription Drug
FDA Application #
ANDA212399
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-25-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 67296-1908-3 identifies a specific commercial package of 30 tablet in 1 bottle of Levothyroxine Sodium, a human prescription drug labeled by Redpharm Drug, Inc. This tablet is formulated for oral use and contains levothyroxine sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Redpharm Drug, Inc on November 25, 2020. The current certification is valid through December 31, 2026.

How is this Redpharm Drug, Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 67296190803. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
67296-1908-3
11-Digit CMS (5-4-2)
67296-1908-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.